Abvc Biopharma Free Cash Flow (FCF) History (ABVC)

Abvc Biopharma reported −$4.2M in free cash flow for fiscal 2023, an increase of $3.3M from the previous fiscal year, with a free cash flow margin of −2760.64%.

View full Abvc Biopharma company overview

Abvc Biopharma free cash flow by year

Abvc Biopharma annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20232023-12-31−$4.2M$3.3M−2760.64%
20222022-12-31−$7.5M$97,139−775.23%
20212021-12-31−$7.6M−$7.6M−2140.33%
20132013-09-30−$37,768$877,706−485.01%
20122012-09-30−$915,474$707,525−16021.60%
20112011-09-30−$1.6M−$574,364−50877.71%
20102010-09-30−$1.0M−7056.76%

Abvc Biopharma free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from −$1.6M to −$4.2M, a net decrease of $2.6M. Abvc Biopharma's latest reported quarter, Q4 2022, generated −$461,158 in free cash flow, a decrease of $461,158 year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Abvc Biopharma filings at SEC.gov ↗